The new Guangdong model indicates that the next round of drug bidding is not optimistic (2)

Source: FDC pharmasia news 2013-06-04 the new bidding system of Guangdong Province may adopt the drug trading mode of Chongqing to provide a platform similar to the stock exchange for hospitals to purchase drugs online, and the government is responsible for the supervision and operation of this platform Imitating the Chongqing model, the bidding work of Guangdong Province will be carried out once a month Moreover, Guangdong Province has modified the Chongqing model in the hope of significantly reducing the drug price by allowing hospitals to select drug dosage forms and specifications but not suppliers In addition to the "winner takes all" bidding rules, Guangdong Province also plans to adopt the price-oriented bidding system in the Anhui model, with all eligible enterprises bidding in the same place "The new leadership of Guangdong Province is optimistic about the characteristics of the Chongqing model of drug exchange and the price control characteristics of the Anhui model and the Fujian model," Peng said But given the importance of Guangdong Province, there is bound to be a heated discussion among stakeholders before a formal agreement can be reached " For EDL bidding, the drug price is scored 90 points, while the quality score is only 10 points For example, in the bidding process, only three quality indicators will be referred to: new GMP certification, hospital coverage and factory price record tracking record, while in the past, 12 quality evaluation indicators will be referred to The bidding price of basic drugs will also be applicable to all medical institutions, not only basic medical institutions However, Mr Peng pointed out that the model "has technical defects and has been proved unsuccessful in Anhui model because the lowest bidding varieties in each quality level will win the bid In addition, there are some problems in the combination of various dosage forms Because different dosage forms may have different bioavailability, they should be treated separately " Mr Peng acknowledged that this form of drug exchange has its own advantages, but he also pointed out that it is unlikely that Guangdong Province will bid once a month, one of the reasons is that it is short of manpower, or because it "has not fully considered the volatility of hospital procurement and the difficulties it may cause to drug distributors." Mr Peng concluded that other provinces are unlikely to fully adopt the Guangdong model, but may draw on part of it The industry condemns the new Guangdong model At present, most multinational enterprises are on the sidelines, while domestic pharmaceutical enterprises are trying their best to modify the draft bidding rules The strongest opposition comes from China Pharmaceutical Industry Research and Development Promotion Association (hereinafter referred to as "China pharmaceutical promotion association") The China Council for the promotion of drugs has submitted research opinions to the Guangdong provincial government, with copies to the State Council, the health and Family Planning Commission (the new Ministry of Health), the Ministry of industry and information technology and the State Food and drug administration According to the research opinion, the draft is inconsistent with the State Council's spirit of encouraging innovation (see: Research opinion of China Council for the promotion of drugs - Chinese version) According to the China Council for the promotion of drugs, the price-oriented bidding system is contrary to the national laws and regulations on drug safety It also criticizes the monthly bidding system, the combination of different dosage forms and the definition of low-cost drugs Mr Peng said: "in an official opinion released on May 23, the China Council for the promotion of drugs pointed out that the Guangdong model not only violates the principles of market economy, such as hospitals cannot choose the manufacturers of drugs they purchase, but also does not conform to the spirit of the No 14 document of the State Council, which overemphasizes the price of products and ignores the quality of products In addition, in terms of technology, compared with local enterprises, Guangdong model is more beneficial to multinational pharmaceutical enterprises " Mr Peng added: "it is speculated that the China Council for the promotion of drugs should have consulted MOH and the State Council's medical reform office about the Guangdong bidding model, and learned that the Guangdong model has not been supported by these two authorities." "Given the strong opposition of many stakeholders in the industry, it may take more than a year for Guangdong Province to finalize its bidding model," Mr Peng predicted Considering that the central government will soon update the national health insurance catalogue, the bidding for non-basic drugs in some provinces may be postponed to next year; in addition, the national health and Family Planning Commission in April this year has asked all provincial governments to suspend the bidding for basic drugs Link to the original text: http://